FP
Financial Post
›Birchtech Reports Fourth Quarter 2025 Financial Results›Colliers Announces Voting Results›Senvest Capital Inc. Reports Results For The Year Ended December 31, 2025›Jushi Holdings Inc. Reports Fourth Quarter and Full Year 2025 Financial Results›Canada takes over the world! Okay… just the movie screens›ITA Airways Joins Star Alliance›Warren Buffett warns he’s watching stability of banking system›AMI presents an emotional and thought-provoking narrative on Medical Assistance in Dying (MAiD) with the documentary The Last Days of April›IGEL Expands its Partnership with Omnissa to Speed Deployments, Strengthen Healthcare Recovery, and Integrate Digital Experience Insights›iA Financial Group has published its 2025 Sustainability and Climate Change Performance reports›Surge Copper Provides Corporate and Operational Update›African Rainbow Minerals Limited to Acquire Shares of Surge Copper Corp.›Virgin Galactic is booking space trips at US$750,000 apiece›NGen Announces $79.5 Million in New AI Projects to Help Canadian Manufacturers Compete Globally›Calls for Teen Social-Media Limits Spread as Perils Grow Clearer›Aluminum Heads for 10% Monthly Surge as Iran War Roils Supplies›Pet Valu® Celebrates 50 Years of Pet Love›EDF Hit by EU Subsidy Probe Into €73 Billion Nuclear Plans›Hotel101 Global Holdings Corp. Takes Next Step for Proposed US$300 Million Series A Perpetual Preferred Share Offering›Biogen to Acquire Apellis, Enhancing the Company’s Growth Portfolio in Immunology and Rare Disease, Bolstering Growth Outlook and Accelerating Expansion into Nephrology
Last updated: Sep 21, 2026, 8:00 p.m.